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Abstract
Background: The fruiting body of Hericium erinaceus has been demonstrated to possess anti-dementia activity in
mouse model of Alzheimer’s disease and people with mild cognitive impairment. However, the therapeutic potential
of Hericium erinaceus mycelia on Alzheimer’s disease remains unclear. In this study, the effects of erinacine A-enriched
Hericium erinaceus mycelia (HE-My) on the pathological changes in APPswe/PS1dE9 transgenic mouse model of
Alzheimer’s disease are studied.
Results: After a 30 day oral administration to 5 month-old female APPswe/PS1dE9 transgenic mice, we found that
HE-My and its ethanol extracts (HE-Et) attenuated cerebral Aβ plaque burden. It’s worth noting that the attenuated
portion of a plaque is the non-compact structure. The level of insulin-degrading enzyme was elevated by both HE-My
and HE-Et in cerebral cortex. On the other hand, the number of plaque-activated microglia and astrocytes in cerebral
cortex and hippocampus were diminished, the ratio of nerve growth factor (NGF) to NGF precursor (proNGF) was
increased and hippocampal neurogenesis was promoted after these administrations. All the mentioned benefits of
these administrations may therefore improve the declined activity of daily living skill in APPswe/PS1dE9 transgenic mice.
Conclusions: These results highlight the therapeutic potential of HE-My and HE-Et on Alzheimer’s disease.
Therefore, the effective components of HE-My and HE-Et are worth to be developed to become a therapeutic
drug for Alzheimer’s disease.
Keywords: Alzheimer’s disease, APPswe/PS1dE9 transgenic mice, Amyloid β, Neurogenesis, Erinacine A-enriched
Hericium erinaceus mycelia, Insulin-degrading enzyme
Background
Alzheimer’s disease (AD), an age-related progressive neuro-
degenerative disorder, is characterized by the formation of
neurofibrillary tangles, extracellular aggregated amyloid-β
(Aβ) plaques, and neural and synaptic loss [1]. The accu-
mulation of Aβ results in neuroinflammation and oxidative
stress. Aβ is a normal product of cellular metabolism de-
rived from the amyloid precursor protein (APP) by the
successive action of the β- and γ-secretases [2]. The ac-
cumulation of Aβ in the brain is then determined by
the rate of Aβ generation versus clearance. Clearance can
be accomplished via three major pathways: proteolytic deg-
radation, microglia-mediated clearance, receptor-mediated
transport across the blood-brain barrier [3].
Compromised neurogenesis presumably takes place
earlier than onset of hallmark lesions or neuronal loss,
and may play a role in the initiation and progression of
neuropathology in AD [4]. Recent studies have shown
that brain levels of nerve growth factor (NGF) precursor
(pro-NGF) are increased in a stage dependent manner in
AD [5], and NGF deprivation leads to cholinergic deficit,
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Aβ deposition, tau hyperphosphorylation and impaired
neurogenesis [6, 7]. Moreover, inflammatory challenge
triggered by Aβ induces the production of proinflamma-
tory cytokines by microglia as well as resident astrocytes
have profound detrimental effects on adult neurogenesis
[8]. Therefore, alteration of ratio of NGF/proNGF, in-
flammatory challenge and compromising neurogenesis
are involved in the developments of AD.
Hericium erinaceus is an edible and medicinal mush-
room with various pharmacological activities in the pre-
vention of many age-associated neurological dysfunctions,
including AD and Parkinson’s disease [9]. Moreover, com-
pounds isolated from its fruiting bodies and mycelia ex-
hibit a potent activity to stimulate NGF expression and
secretion in vitro and in vivo [10, 11]. Recent studies dem-
onstrated anti-dementia activity of its fruiting bodies in
mice with cognitive deficits induced by Aβ and in people
with mild cognition impairment [12, 13]. However, the
anti-dementia activity of Hericium erinaceus mycelia
remained unclear.
In the present study, we investigated the potentials of
erinacin A-enriched Hericium erinaceus mycelia (HE-My)
and it ethanol extracts (HE-Et) on AD-related pathologies
in 5 month-old APPswe/PS1dE9 (APP/PS1) double trans-
genic mouse, a transgenic mouse model of AD expressing
two mutations in the human APP as well as two human
presenilin 1, exhibiting impaired exploratory behavior,
spatial memory and synaptic function [14–16]. Our data
suggests that HE-My and HE-Et ameliorated Aβ plaques
via increasing the level of insulin degrading enzyme (IDE)
and microglia-mediated clearance. Additionally, HE-My
and HE-Et also elevated NGF/proNGF ratio. All the alter-
ation may result in promotion of neurogenesis and im-
proving the decline of activity of daily living (ADL) skill.
Methods
Sample preparation
Hericium erinaceus (BCRC 35669) purchased from Bior-
esources Collection and Research Center (BCRC) in Food
Industry Research and Development Institute (Hsinchu,
Taiwan) were maintained and cultivated on potato dex-
trose agar at 26 °C for 15 days according to the method
described earlier [17]. After incubation, a mycelial agar
block (1 cm3) was removed, transferred to a 2-L Erlen-
meyer flask containing 1.3 L synthetic medium (composed
of 0.25 % yeast extract, 4.5 % glucose, 0.5 % soybean
powder, 0.25 % peptone and 0.05 % MgSO4, adjusted to
pH 4.5) and incubated for 5 days at 26 °C on a rotary
shaker (120 rpm). The fermentation process was then
scaled up from a 2-L shake flask to 500-L and 20-ton
fermenters for 5 and 12 days, respectively. At the end
of the fermentation process, the mycelia were then har-
vested, lyophilized, grounded into powder, and stored
in a desiccator at room temperature (HE-My). The
proximate composition analysis, including ash, total
protein, lipids, and carbohydrates of the freeze-dried
mycelia were determined according to official AOAC
methods. The dry sample was then analyzed by UPLC
to evaluate the content in the mycelia based on its dry
weight. HE-My was extracted four times with 90 %
ethanol under reflux to give the ethanol extract (HE-Et).
Their chemical finger prints were determined (Fig. 1).
Three active components in HE-Et were identified and
were compared to standards. The identification of eri-
nacine A (HE-A), erinacine C (HE-C) and erinacine S
(HE-S) in HE-Et using NMR and LC-MS-MS have been
previously described [17, 18]. The HE-My (containing
19 mg/g HE-A) and HE-Et (containing 104.4 mg/g HE-A)
were dissolved in vehicle (3 % DMSO/10 % cremophor EL
(Sigma)/87.5 % D5W (5 % dextrose in water, pH 7.2) with
vigorous shaking in order to get a final concentration of
3 mg · ml−1 (HE-A) or 30 mg · ml−1 (HE-My and HE-Et)
before its administration to mice.
Animal management and administration
The Institutional Animal Care and Use Committee at
the National Research Institution of Chinese Medicine
approved the animal protocol (IACUC No: 100-A-04
and 102-417-3). The APPswe/PS1ΔE9 double transgenic
mouse model (APP/PS1) of AD was purchased from
Jackson Laboratory (No. 005864) that expressed a chimeric
mouse/human APP695 harboring the Swedish K670M/
N671L mutations (APPswe) and human PS1 with the
exon-9 deletion mutation (PS1ΔE9). Breeding gender ratio
was a male with two females in one cage. Experiments were
conducted using wild type (WT) siblings and AD trans-
genic female C57BL/6 J mice. The animals were housed
under controlled room temperature (24 ± 1 °C) and humid-
ity (55–65 %) with 12:12 h (07:00–19:00) light–dark cycle.
All mice were provided with commercially available rodent
normal chow diet and water ad libitum.
To explore the effect of HE-My and HE-Et, 5 months
old APP/PS1 mice were fed with HE-My and HE-Et
(300 mg/kg/day) for 30 days for pathological test, and
5-bromo-2′-deoxyuridine (BrdU; Sigma) was injected
intraperitoneally at 50 mg/kg/day at the last 7 days. For
behavior test, 5 months old APP/PS1 mice were fed
with HE-My (300 mg/kg/day) for 70–90 days.
Tissue processing
After administration by oral gavage to 5 month-old mice
for 30 days, 5-bromo-2′-deoxyuridine (BrdU; Sigma)
was injected intraperitoneally (50 mg/kg/day) at the last
7 days, then the mice were deeply anesthetized with
chloral hydrate and then sacrificed by transcardial perfu-
sion with saline at pH 7.4. Mice brain was removed and
one hemisphere was homogenized in H-Buffer (320 mM
sucrose, 2 mM EDTA, 20 mM Tris-HCl (pH 7.4), 1 mM
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PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin) for Aβ
ELISA and immunoblots. Another hemisphere was
processed for histochemical and immunohistochemical
staining. Dissected brains were immersed in 4 % for-
maldehyde for 18 h at 4 °C, then cryoprotected in sucrose
before being sectioned into 30 μm thick free-floating
sections.
Thioflavin S staining
Thioflavin S (Ths; Sigma) is widely used to detect amyloid
plaque deposition [19]. For triple immunofluorescent
staining with thioflavin S, Aβ plaque and microglia,
dried sections were stained with fresh, filtered 1 % thio-
flavin S in water for 60 min, and then washed twice with
70 % ethanol for 5 min each, twice with water for 2 min
each, twice with PBS for 5 min each. The sections were
then incubated in blocking buffer and antibody dilution
buffer with corresponding antibodies, as mentioned above.
Immunohistochemistry
The mice were sacrificed by transcardial perfusion with
saline at pH 7.4. One hemisphere of brain was homoge-
nized in H-Buffer (320 mM sucrose, 2 mM EDTA,
20 mM Tris–HCl (pH 7.4), 1 mM PMSF, 5 μg/ml leu-
peptin, 5 μg/ml aprotinin) for Aβ ELISA and immuno-
blots. Another hemisphere of brain was processed for
immunohistochemical detection. Dissected brains were
immersed in 4 % formaldehyde for 18 h at 4 °C, then
cryoprotected in sucrose before being sectioned into 30 μm
thick free-floating sections. Sections were blocked in block-
ing buffer (PBS with 3 % normal donkey serum, 1 % bovine
serum albumin (BSA) and 0.3 % Triton X-100) for 60 min
and incubated overnight at 4 °C in antibody dilution buffer
(PBS with 1 % normal donkey serum, 1 % BSA and 0.3 %
Triton X-100) with primary antibodies, including mouse
monoclonal anti-GFAP antibody (1:300, Millipore) and
anti-Aβ1-16 antibody (AB10, 1:300, Millipore), goat anti-
Iba-1 antibody (1:300, abcam). Sections were then incu-
bated in antibody dilution buffer containing Hoechst33258
(Invitrogen, 2 μg/ml), Fluorescein isothiocyanate-
conjugated donkey anti-mouse IgG and RRX-conjugated
donkey anti-rabbit IgG or Alexa Fluor 647-conjugated don-
key anti-goat IgG (1:300; Jackson ImmunoResearch) in the
dark for 2 h at room temperature. Sections were then
washed with PBS containing 0.01 % Triton X-100 and
mounted with Aqua Poly/Mount (Polyscience Inc., War-
rington, PA, USA). Fluorescent images of immunohisto-
chemistry and ThS staining were taken using a Zeiss
LSM 780 confocal microscopy (Jena, Germany). Amyloid
plaque deposition was quantified using ImageJ software.
The amyloid plaque burden indicates the AB10-reactive
or ThS-positive area normalized to the total area.
Fig. 1 The representative chemical finger prints and the structure of the major components of Hericium erinaceus mycelium. a. UPLC chromatogram
of HE-Et was carried out on a Thermo syncronis C18 (2.1 × 100 mm) column in Waters AcQuity Ultra Performance LC system with a diode array
detector, monitored at 210 nm. The mobile phase consisted of 0.1 % phosphate water (a) and acetonitrile (b) using a gradient elution of 20–55 % B at
0–2 min, 55–90 % B at 2–9 min, 90–100 % acetonitrile at 9–10 min. The flow rate was 0.4 ml/min. Three active components: HE-A, HE-C and HE-S were
identified and compared to the standards, and their structure was shown in b
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For detection of BrdU-positive cells, tissue sections
were incubated in 10 mM sodium citrate (pH 6.0) at
80 °C for 30 min, and subsequently in 2 M HCl at 37 °C
for 30 min. The sections were then incubated in block-
ing buffer and antibody dilution buffer with primary
antibodies, including mouse monoclonal antibodies to
BrdU (1:500, Senta Cruz) and rabbit polyclonal antibody
to doublecortin (DCX, 1:500, abcam), and corresponding
secondary antibodies, as mentioned above. The number
of BrdU- or DCX-positive in the subgranular zone
(SGZ) of dentate gyrus was quantified and revealed as
the linear density of BrdU- or DCX-positive cells per
millimeter of SGZ.
Quantification of ThS- and AB10-stained plaques
The quantification of ThS- and AB10-stained plaques
was conducted individually. At least 3 coronal brain sec-
tions from each mouse were used for analysis. Each
image was adjusted to the threshold for pixel detection
(threshold setting for ThS-positive signal is 60; threshold
setting for AB10-positive signal is 40). To eliminate
background, particle less than 100 pixels (approximately
70 μm2) was excluded. Occupied area by ThS- or AB10-
stained signal was divided by the full area of interest, in-
cluding cortex and hippocampus, and represented as
percentage.
Mesurement of Aβ1–42 levels
Two-step sequential extraction of the brain Aβ using
2 % SDS and 70 % formic acid (FA; Sigma) was processed
as described previously [20]. Briefly, cortical homogenate
was mixed with equal volume of 4 % SDS in H-buffer con-
taining protease inhibitor. The sample was then sonicated
and centrifuged at 100,000 × g for 60 min at 4 °C. The
supernatant was considered SDS-soluble fraction. The
SDS-insoluble pellet was further resuspended in 70 % FA
and centrifuged at 100,000 × g for 60 min at 4 °C. The
supernatant was collected and neutralized with 1 M Tris,
pH 11. SDS-soluble and SDS-insoluble fractions were
stored at −80 °C until sandwich ELISA analysis. Aβ level
was measured by a sensitive fluorescence based sandwich
ELISA assay using a kit (Human β- Amyloid 1–42,
Invitrogen KHB3442). The detailed experiments were
performed according to the manufacturer’s protocol.
Immunoblots
For Western blot analysis, samples (30 μg protein) were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and were then transferred to PVDF mem-
branes. The primary antibodies used were as follows:
rabbit anti-Iba-1 antibody (Wako), rabbit anti-NGF
antibody, rabbit anti-GFAP antibody, mouse anti-APP
antibody, rabbit anti-CTF antibody, rabbit anti-NEP
antibody, rabbit anti-IDE antibody (Millipore) and mouse
anti-β-actin antibody (Novus Biologicals). The secondary
antibodies were anti-rabbit IgG antibody conjugated
with horseradish peroxidase (HRP; GE Healthcare) and
anti-mouse IgG antibody conjugated with HRP (Jackson
ImmunoResearch). Enhanced chemiluminescence detection
reagents (GE Healthcare) were used for detection. Bands
were quantified using Fujifilm LAS-3000 Luminescent
Image Analyzer (Tokyo, Japan).
Nesting test
After oral gavage administration for 81 days, mice were
assessed for nesting task as described previously [21].
Two nestlets (approximately 5 g) were placed into cage
at 1 h before dark cycle, and then the nest score and the
weight of unshredded nestlets were determined after
overnight. The nest quality was assessed on a 1–5 rating
scale, with 1, nestlet was not noticeable touched; 2, nest-
let was partially shredded and scattered on the floor; 3,
nestlet was mostly shredded but only flat nest was build;
4, nest was identifiable but flat; and 5, nest was build in
a burrow.
Statistical analysis
The results are expressed as the mean ± standard deviation
(S.D.) and were analyzed by analysis of variance (ANOVA)
with post-hoc Bonferroni multiple comparisons tests.
Results
HE-My and HE-Et reduce the number of AB10-stained
plaque in cerebral cortex and hippocampus of APP/PS1
mice
In APP/PS1 transgenic mice model, plaques are well
established and visible at 6 months old. Therefore,
5 months-old APP/PS1 mice were fed with 300 mg/kg/
day HE-My or HE-Et for 30 days to explore their effects
on plaque burden by double staining with AB10-antibody
and ThS to observe the structure of whole plaque and its
compact core, respectively. The number of AB10-stained
plaque with diameter bigger than 100 pixel (68 μm) in
cerebral cortex and hippocampus of APP/PS1 mice were
counted.
The treatment did not significantly change the body
weight, suggesting that these treatments have no obvious
side effect (data not shown). However, the number and
burden of whole plaque stained by AB-10, but not com-
pact core stained by ThS, were significantly reduced
after 30-day administration of HE-My or HE-Et (Fig. 2a
and b). Compared with vehicle-treated mice, HE-My
treatment decreased burden and number of whole
plaque by 38.6 ± 9.3 % and 34.8 ± 13.4 %, respectively.
More effectively, HE-Et treatment decreased burden and
number of whole plaque by 55.8 ± 15.2 % and 43.5 ±
15.6 %, respectively.
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To identify the detail structure of whole plaque and
its compact core, the image of the double stained
plaques were displayed in both maximum projection of
3-dimensional stack (Fig. 2C, a–c) and confocal cross
sections in xy, yz, and xz (Fig. 2C, d–f ). The result
showed that a typical plaque was composed by a ThS-
stained compact core and an AB10-imunostained fila-
mentary structure, which surround the compact core.
HE-My and HE-Et reduce the size of AB10-stained plaque
in cerebral cortex and hippocampus of APP/PS1 mice
Sixty double stained plaques of the representative slice
of vehicle- and HE-Et-treated mice were selected by size
to reveal the difference of plaque conformation (Fig. 3a).
The result showed that the non-compact structure of pla-
ques was significantly reduced by the treatment of HE-Et.
A scatter plot of the plaque size in μm2 with compact core
(ThS-staining) against whole plaque (AB-10-staining) was
plotted to reveal the morphological alteration of an in-
dividual plaque before and after HE-Et treatment. The
result showed that the HE-Et modulated structure con-
fined in the AB10-stained non-compact part of whole
plaque but not the ThS-stained compact core (Fig. 3b).
The similar result was found in the HE-My treated mice
(data not shown).
For examining the involvement of Aβ1–42 in the
plaque structure, soluble and insoluble Aβ were iso-
lated from the cortex of APP/PS1 mice and the Aβ
level was detected using Aβ1–42-ELISA analysis (Fig. 3c).
The results showed that administration of HE-My
significantly reduced the level of soluble, but not insol-
uble Aβ1–42. Alternatively, no significant effect of HE-
Et on the level of both soluble and insoluble Aβ was
observed.
Fig. 2 HE-Et and HE-My reduce amyloid plaque burden in the area include the cerebral cortex and hippocampus of APP/PS1 mice. Five month-old
APP/PS1 mice were orally administered with vehicle (Veh, n = 6), HE-Et (n = 5) and HE-My (n = 6) for 30 days. A. The representative fluorescent images
of amyloid plaques detected by thioflavin S (ThS) staining (white in a, e and i, and green in c, d, g, h, k and l) and immunohistochemical staining with
AB-10 antibody (white in b, f and j, red in c, d, g, h, k and l) in the area including parietal cortex and hippocampus. Sale bar: 500 μm. A typical plaque is
magnified and shows in the right side of each image. Sale bar: 20 μm. B. shows both the plaque number and burden in ThS- and AB-10-stained
semi-cerebral sphere calculated by image analysis software. Plaque burden is displayed as a percentage of the area occupied by ThS- or AB-10-stained
signal in the full area of interest. C. The structure of amyloid plaque in the cerebral cortex of APP/PS1 mice. The amyloid plaque in cerebral cortex of
6 months-old APP/PS1 mice was detected by ThS-staining (white in a and d, and green in c and f) and immunohistochemical staining with
AB-10 antibody (white in b and e, and red in c and f). Upper panels show the representative Z-projection (3 dimensions, XYZ, A-C) of a typical
plaque. Lower panels show the 2 dimensional images (XY, XZ, and YZ, D-F). The image indicated by arrow indicated the putative plaque unit.
Sale bar: 10 μm. Single fluorescent images were presented as grayscale to enhance resolution
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HE-Et and HE-My reduce Aβ-associated glial cells in
APP/PS1 mice
Next, we evaluated the effects of HE-Et and HE-My on
plaque-associated clusters of activated microglia and re-
active astrocytes by immunohistochemical staining with
AB-10, Iba-1 and GFAP antibodies, respectively. The
image revealed that both the activated astrocyte and
microglia formed cluster surrounding plaque in the area
including cortex and hippocampus (Fig. 4a and b). HE-Et
treatment decreases the number of Iba-1-positive micro-
glia cluster and GFAP-positive astrocyte cluster by 25.2 ±
9.4 % and 40.0 ± 13.5 %, respectively (Fig. 4c). HE-My
treatment decreases the number of microglia and astro-
cyte cluster by 19.4 ± 13.9 % and 43.3 ± 9.0 %, respectively
(Fig. 4c). To determine the total reducing of microglia
activation and astrocytes reactivity by HE-My and HE-Et,
the cortex homogenates of the treated mice were exam-
ined by immunoblot using anti-Iba-1 and anti-GFAP
antibodies. The result showed that the level of micro-
glia activation was decreased by HE-Et and HE-My to
47.9 ± 12.9 % and 37.9 ± 7.9 % of control, respectively
(Fig. 4d). In contrast, the level of astrocytes reactivity
was reduced to 64.3 ± 12.1 % and 55.7 ± 20.8 % of
control.
HE-Et and HE-My promote the level of Aβ degrading
protein in cortex of APP/PS1 mice
To understand the mechanisms by which HE-Et and HE-
My reducing Aβ plaque in APP/PS1 mice, we assessed the
proteins involving APP processing and Aβ degradation.
Fig 3 HE-Et reduces size of AB-10-stained plaque in the area including cerebral cortex and hippocampus of APP/PS1 mice. a. The representative
images of ThS (green)- and AB-10 (red)-stained plaques (60 for each) selected in order of decreasing size from the area include the cerebral cortex
and hippocampus of vehicle- and HE-Et-treated APP/PS1 mice. b. A scatter plot of ThS- and AB-10-stained areas from representative samples with
vehicle and HE-Et treatments (solid lines: linear regression lines; dashed lines: 95 % confidence intervals; R2 = 0.8224 for vehicle and R2 = 0.9079 for
HE-Et). c. The levels of soluble and insoluble Aβ1-42 determined by ELISA. The results are the mean ± S.D. Significant differences between treated
and control (Veh) groups are indicated by *, p < 0.05
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APP processing was examined by the levels of full
length APP, and C-terminal fragments (CTF)-α and
CTF-β. The result revealed that HE-Et and HE-My
treatment did not affect the levels of APP, CTF-α and
CTF-β. Next, we detected the levels of Aβ degrading
enzymes including IDE and neprilysin. The result
showed that HE-Et and HE-My treatment increased the
level of IDE in cortex by 127.7 ± 81.4 % and 103.9 ±
30.9 %, respectively (Fig. 5a). However, no effect on the
level of neprilysin was observed.
Fig. 4 HE-Et and HE-My alleviate amyloid plaque-associated glial activation in the area including hippocampal and cortex of APP/PS1 mice. Five
month-old APP/PS1 mice were orally administered with vehicle (Veh, n = 6), HE-Et (n = 5) and HE-My (n = 6) for 30 days. Amyloid plaques were
detected by immunohistochemical staining with AB-10 antibody (blue). Microglia and reactive astrocytes were detected by immunohistochemical
staining with Iba-1 antibody (red) and GFAP antibody (green), respectively. a. The representative immunostaining images of hippocampus and partial
cortex. Sale bar: 500 μm. b. The enlarged views of a typical cluster which is indicated in panel a (arrow). Sale bar: 50 μm. c. Both the number of
microglial and astroglial cluster in semi-cerebral sphere calculated by image analysis software. d. The immunoblotting of Iba-1 and GFAP.
Representative immunoblots of the Iba-1, GFAP and β-actin were showed (left panel). The relative levels of Iba-1 and GFAP were expressed
as percentage of control (Veh) (right panel). The results are the mean ± S.D. Significant differences between treated and control (Veh) groups
are indicated by *, p < 0.05; **, p < 0.01; ***, p < 0.001
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HE-Et and HE-My increase NGF/proNGF ratio and promote
hippocampal neurogenesis in APP/PS1 mice
The levels of NGF and proNGF were analyzed by im-
munoblotting. HE-Et and HE-My significantly increase
NGF/proNGF ratio by 124.7 ± 54.1 % and 109.9 ± 25.7 %,
respectively (Fig. 5b).
We hypothesized that the increased NGF/proNGF
ratio and declined microglial activation may promote
hippocampal neurogenesis. Therefore, newly born granu-
lar neurons and proliferating type 2 progenitors in the
subgranular zone (SGZ) was assessed by immunohisto-
chemical staining using anti-DCX and anti-BrdU anti-
body, respectively. We found that the number of both
newly born granular neurons (DCX-positive) and pro-
liferating type 2 progenitors (BrdU-positive) were de-
clined in APP/PS1 mice as compared with the wild
type mice (Fig. 6). However, the declined number of
the DCX-, BrdU-, and BrdU/DCX-double positive neu-
rons were recovered after the treatment of HE-My and
HE-Et.
HE-My recovers activity of daily living decline in APP/PS1
mice
Nesting behaviors engage a broad network of brain re-
gions; have previously been applied on evaluating the
daily living skills of AD transgenic mice. Therefore,
nesting task was performed. The result showed that
APP/PS1 mice had lower nesting score and less nestlet
shredding than WT mice. However, HE-My-treated
APP/PS1 mice recovered the decline of both nesting
score (Fig. 7a and b) and nestlet shredding (Fig. 7a and c).
Discussion
Our results reveal that the administrations of HE-Et or
HE-My to APP/PS1 mice for 30 days eliminated amyloid
plaque burden, prevented recruitments and activations
of plaque-associated microglia and astrocytes, promoted
the expression of IDE, the NGF/proNGF ratio, and the
proliferation of neuron progenitors and the number of
newly born neurons in dentate gyrus. Finally, we found
that the administrations of HE-My for 81 days recovered
Fig 5 Effects of HE-Et and HE-My on the level of the proteins regulating Aβ accumulation and the level of NGF in cerebral cortex of APP/PS1 mice.
Five months-old APP/PS1 mice were orally administered with vehicle (Veh, n = 6), HE-Et (n = 5) and HE-My (n = 5) for 30 days. Cortex was removed and
homogenized, and the proteins involving in amyloidogenesis and amyloid clearance and NGF maturation in lysates were analyzed by immunoblotting.
a The representative immunoblots of APP, CTF-α, −β, IDE, neprilysin and β-actin (left panel). The level of APP, CTF-α and -β, IDE and neprilysin was
presented as percentage of control (Veh) (right panel). b The representative immunoblots of the proNGF, NGF and β-actin (left panel). The relative
level of NGF/proNGF ratio was presented as percentage of control (Veh) (right panel). The results are the mean ± S.D. Significant differences between
treated and control (Veh) groups are indicated by *, p < 0.05; **, p < 0.01
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Fig. 6 HE-My and HE-Et promotes hippocampal neurogenesis in APP/PS1 mice. Five months old wild type (WT) or APP/PS1 mice were orally
administered with vehicle (Veh, n = 6), HE-Et (n = 6) and HE-My (n = 6) for 30 days. Hippocampal neurogenesis was detected by immunohistochemical
staining with doublecortin (DCX) antibody (red) and BrdU antibody (green). a. The representative immunostaining images of dentate gyrus in wild type
(WT, n =7) mice and APP/PS1 mice treated with vehicle (Veh), HE-Et and HE-My. Arrow indicates DCX-labeled newly born neuron; arrow head indicates
proliferating type 2 neuroprogenitor; double arrow head indicates the newly born neuron immediately after proliferation; hollow arrow indicates
proliferating cells other than neuroprogenitor. Scale bar: 100 μm. ML, molecular layer; UGL, upper blade granular cell layer; LGL, SGZ, subgranular
zone; lower blade granular cell layer. b. The number of BrdU positive cells, doublecortin positive cells and the cells with double labeling (cell
number/mm SGZ). The results are the mean ± SD. Significant differences between wild type (WT) and APP/PS1 groups are indicated by *, p < 0.05.
Significant differences between treated and control (Veh) groups are indicated by #, p < 0.05; ##, p < 0.01
Fig. 7 The deficit on nest construction displayed by APP/PS1 mice were improved by HE-My treatment. Five months old wild type (WT) or APP/PS1 mice
were orally administered with vehicle (Veh, n= 6) or HE-My (n= 6) for 81 days and then nest construction test were performed. The representative
images of the nest construction (a), the nest score (b) and unshredded nestlet (c) were shown. The results are the mean ± SD. Significant differences
between WT (n = 8) and APP/PS1 groups are indicated by **, p < 0.01; ***, p < 0.001. Significant differences between treated and control (Veh) groups
are indicated by #, p < 0.05
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the deficits on activity of daily living skills in APP/PS1
mice.
Our previous study shows that 300 mg/kg HE-My
display the best/highest neuroprotective activity against
ischemia reperfusion injury [22]. The safe dose of erina-
cine A-enriched Hericium erinaceus was as high as
3000 mg/kg in a 28-day oral feeding study in Sprague-
Dawley rats [17]. Furthermore our previous report showed
that 30 mg/kg erinacine A and S process similar activity to
reduce Aβ deposition and increase IDE expression [18].
HE-My and HE-Et contain 19 mg/g and 104.4 mg/g of
HE-A, respectively. Hence, it is likely that the ingredients
form HE-My or HE-Et process similar activity and HE-My
or HE-Et (300 mg/kg/day) reach ceiling effect on Aβ clear-
ance. Therefore, we chose 300 mg/kg to test its effect.
Previous reports show that female APP/PS1 mice have
more deposition of amyloid plaque than that of male
APP/PS1 mice [23–25], and both male and female
APP/PS1 mice reveal the similar impairment in spatial
learning and memory [23]. Additionally, both genders
reveal good activity to build nest [26, 27]. Therefore, we
think female APP/PS1 mice is also suitable as a model to
evaluate the effect of treatment on AD-like pathology.
Previous studies showed that H. erinaceus mycelia
and its components possess the activity to stimulate
NGF expression and secretion in vitro and in vivo [10].
In our present study, it is evidenced that HE-My and its
components increase the NGF/proNGF ratio (Fig. 5b).
Recent studies pointed out that the NGF metabolic dys-
function is associated with AD and Down syndrome
[28]. Mature NGF is derived from proNGF by some
convertases, such as plasmin and furin, and degraded
by matrix metalloprotease 9. However, it is still unclear
whether H. erinaceus mycelia and its components in-
duce the expression of plasmin and furin, or reduce the
expression of MMP-9.
The structure of amyloid plaque [29] and the sequen-
tial clustering of plaque-associated activated microglia
and reactive astrocytes [30] have been studied by some
previous works. Those works suggested that the accu-
mulation of Aβ may lead to abnormal neuroinflamma-
tion and oxidative stress, and the microglial activation is
highly associated with the accumulation of Aβ. In our
present study, it is evident that the glial cluster is con-
structed by at least four sequential layers (i.e. amyloid
compact core with radiating arm; amyloid none β-pleated
sheet filamentary structure; microglial clustering; and
astroglial clustering) (Figs. 2c and 4b). The activity of
HE-My and HE-Et to reduce the filamentary structure
of amyloid plaque burden in both cortex and hippocam-
pus is a novel finding.
Although Aβ staining by both ThS and AB10 cannot
functionally distinguish between increased phagocytosis
and impaired degradation, our results showed that
HE-My and HE-Et substantially altered the character-
istics of Aβ plaque deposition in the APP/PS1 mice
(Figs. 2 and 3). HE-My and He-Et significantly reduced
the non-compact structure of amyloid plaque (Fig. 3b).
Additionally, HE-My-treated APP/PS1 mice showed a
40 % reduction in brain concentrations of soluble forms of
Aβ1–42 (Fig. 3c).
AD is characterized by elevated levels of Aβ that are
produced by β- and γ-secretases [31]. As a corollary, any
approach aimed at blocking the production of Aβ by
interfering with these enzymes could be seen as a valid
therapeutic strategy. On the other hand, activation of
α-secretase is another strategy to block the production
of Aβ. In our present study, HE-My and HE-Et attenuated
the AB10-stained non-compact plaque structure and re-
duced the level of soluble form Aβ1–42 may be attributable
to the inhibition of β- or γ-secretase or activation of
α-secretase. For determining this effect, the levels of APP,
CTF-α and -β were measured. However, the outcome was
negative. However, HE-Et and HE-My were found to
promote IDE expression suggesting that Aβ clearance
by degradation might be involved in the Aβ reduction
effect. IDE is the degrading enzyme for Aβ and APP
intracellular domain (AICD) [32, 33]. IDE is located in
the cytosol and mitochondria [34], and a small propor-
tion of IDE also secreted out from cells [35]. Agonists
of the PPARγ pathway have been shown to enhance Aβ
clearance by a mechanism that appeared to implicate
IDE. Moreover, Notch signaling pathway may also regu-
late IDE expression [36]. The data establishing an in-
volvement of IDE in Aβ degradation in vivo are very
strong. Hence, up-regulation of IDE activity remains to
be a therapeutic choice [37]. IDE knockout mice and
rat with partial loss-of-function mutations in IDE reveal
cerebral Aβ accumulation by 50 % [38]. In contrast,
previous work demonstrated that two-fold increase of
IDE via transgenic over-expression reduces obviously
50 % Aβ deposition in APP transgenic mice [37]. There-
fore, it is likely that the two-fold increase of IDE expres-
sion after HE-My or HE-Et treatment may attenuate
amyloid plaque burden. It has been reported that with age
or after some insults, level of IDE in the brain reduce sig-
nificantly [39]. In our present study, APP/PS1 transgenic
mice, IDE was up-regulated as compared to the wild type
mice (Data not shown). This result is consistent with the
previous report that in APPswe/PSEN1(A246E) transgenic
mice, IDE was up-regulated by Aβ [40].
Recent evidence suggests that impaired clearance may
be the driving force behind sporadic AD [41]. In addition
to phagocytosis, microglia also contribute to Aβ clearance
through proteolytic enzymes, including IDE and neprilysin
[42]. In the present study, we found that HE-My and HE-Et
promote IDE expression, suggesting that Aβ clearance by
IDE degradation may be involved in the Aβ reduction
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effect. PPARγ pathway and Notch signaling have been
found to enhance IDE expression in neurons [43, 44].
However, more study is required to reveal the mechanism
mediates HE-My and HE-Et promoted IDE expression.
HE-My and HE-Et were found to promote hippocam-
pal neurogenesis (Fig. 6). Recent study found that APP
could function to influence neurogenesis via its two sep-
arate domains, sAPPα and AICD. The sAPPα was shown
to be neuroprotective and important to neurogenesis,
whereas AICD was found to negatively modulate neuro-
genesis [45]. In our present study, however, administra-
tion of HE-Et and HE-My did not significantly decreased
the level of CTF-α and CTF-β, which are substrates for
γ-secretase to produce AICD. Therefore, neurogenesis
may not be promoted by the decrease of AICD after
the administration of HE-Et or HE-My. On the other
hand, inflammatory challenge triggered by Aβ induces
the production of proinflammatory cytokines by micro-
glia as well as resident astrocytes have profound detri-
mental effects on adult neurogenesis [46].
We focus on species-specific nest building activity be-
cause those are spontaneous hippocampus-dependent
behaviors [21] that have been proposed to be equivalent
to activities of daily living (ADL) skills in humans [47],
and the loss of ADL skills is the warning sign of AD in
clinical [48]. Moreover, the deficits in nesting behaviors
have been shown in APP/PS1 mice [26, 49] and Tg2576
transgenic mice [50]. In our unpublished data, HE-Et or
erinacine A also improved the nesting behavior with
similar activity. Besides in hippocampus, nesting tests
are sensitive to lesions in medial prefrontal cortex and
various regions including septum, respectively [21, 26].
We found that HE-My restored nesting behavior (Fig. 7),
suggesting that HE-My may improve the impairment in
multiple brain regions in APP/PS1 mice.
Conclusion
Our results suggested that HE-My reduced cortical and
hippocampal amyloid plaque burden through increasing
the level of IDE, and increase NGF maturation and
hippocampal neurogenesis in APP/PS1 mice. We also
show that HE-My recovers behavioral deficits in APP/PS1
mice. These findings raise the possibility that HE-My may
have therapeutic potential for treating AD as well as the
other neurodegenerative diseases.
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